NFL Biosciences SA (FR:ALNFL) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
NFL Biosciences SA has made significant progress in the first half of 2024 with its smoking cessation drug NFL-101, successfully completing Phase 2 trials and preparing for Phase 3, showing comparable efficacy to Champix without the side effects. The company also raised €3 million through a capital increase and is working on co-developing NFL-301, a treatment for excessive alcohol consumption, with plans aligned with FDA guidance. With these developments, NFL Biosciences extends its cash runway to the third quarter of 2025.
For further insights into FR:ALNFL stock, check out TipRanks’ Stock Analysis page.